CAR-T Followed by Bispecific Antibodies
Condition(s):Large B-cell Lymphoma; DLBCL – Diffuse Large B Cell LymphomaLast Updated:December 19, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Large B-cell Lymphoma; DLBCL – Diffuse Large B Cell LymphomaLast Updated:December 19, 2023Recruiting
Condition(s):Non-Hodgkin LymphomaLast Updated:March 27, 2024Recruiting
Condition(s):Diffuse Large B-Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell LymphomaLast Updated:March 20, 2024Recruiting
Condition(s):CAR-T Therapy ComplicationsLast Updated:May 30, 2023Recruiting
Condition(s):Diffuse Large-Cell Lymphoma; Primary Mediastinal Large B-Cell Lymphoma (PMBCL); Transformed Follicular Lymphoma (TFL); High-grade B-cell Lymphoma (HGBCL); Follicular LymphomaLast Updated:February 22, 2024Recruiting
Condition(s):Refractory Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaLast Updated:February 22, 2024Recruiting
Condition(s):Ann Arbor Stage III Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation; Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Grade 3b Follicular Lymphoma; HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Intravascular Large B-Cell Lymphoma; Lymphoplasmacytic Lymphoma; Nodular Lymphocyte Predominant B-Cell Lymphoma; Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type; T-Cell/Histiocyte-Rich Large B-Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell LymphomaLast Updated:March 26, 2024Recruiting
Condition(s):Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Grade 3b Follicular Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified; Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type; Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma; Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Refractory Grade 3b Follicular Lymphoma; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified; Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type; Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell LymphomaLast Updated:November 1, 2023Recruiting
Condition(s):Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent High Grade B-Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Aggressive B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaLast Updated:November 14, 2023Recruiting
Condition(s):Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Aggressive Non-Hodgkin Lymphoma; Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Aggressive Non-Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell LymphomaLast Updated:February 14, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.